ArticlePharmaceuticals (Basel, Switzerland)2013
A review of therapeutic aptamer conjugates with emphasis on new approaches.
Article in Pharmaceuticals (Basel, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 110 citations in OpenAlex.
- Aptamer targeting proprotein convertase subtilisin/kexin type 9:Research in pharmaceutical sciences · 2026Article
- Nanoparticles-assisted SELEX strategies for aptamer screening: a comprehensive review.Mikrochimica acta · 2026Review
- A Novel Aptamer Selection Strategy forMolecules (Basel, Switzerland) · 2025Article
- Rejuvenating the Activity of Usual Antibiotics on Resistant Gram-Negative Bacteria: Recent Issues and Perspectives.International journal of molecular sciences · 2023Review
- The Landscape of Nucleic-Acid-Based Aptamers for Treatment of Hematologic Malignancies: Challenges and Future Directions.Bioengineering (Basel, Switzerland) · 2022Review
- Profiling Cancer Cells by Cell-SELEX: Use of Aptamers for Discovery of Actionable Biomarkers and Therapeutic Applications Thereof.Pharmaceutics · 2021Review
- Modified internucleoside linkages for nuclease-resistant oligonucleotides.RSC chemical biology · 2021Review
- A DNA Aptamer for Cyclic Adenosine Monophosphate that Shows Adaptive Recognition.Chembiochem : a European journal of chemical biology · 2020Article
- Fluorogenic RNA Aptamers: A Nano-platform for Fabrication of Simple and Combinatorial Logic Gates.Nanomaterials (Basel, Switzerland) · 2018Article
- Targeting HMGA protein inhibits retinoblastoma cell proliferation.RSC advances · 2018Article
- Potential Inherent Stimulation of the Innate Immune System by Nucleic Acid Aptamers and Possible Corrective Approaches.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Targeting the polyadenylation factor EhCFIm25 with RNA aptamers controls survival in Entamoeba histolytica.Scientific reports · 2018Article
- Aptamer Therapeutics in Cancer: Current and Future.Cancers · 2018Review
- Toward the Selection of Cell Targeting Aptamers with Extended Biological Functionalities to Facilitate Endosomal Escape of Cargoes.Biomedicines · 2017Review
- Virus-like particles: Next-generation nanoparticles for targeted therapeutic delivery.Bioengineering & translational medicine · 2017Review
- Orchestrating a Symphony on a Single Conjugate: Aptamer Targeting, Gene Silencing, and Immunomodulation to Enhance Antitumor Response.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Article
- Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer.Pharmaceuticals (Basel, Switzerland) · 2016Article
- Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia.Biomaterials · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The potential to emulate or enhance antibodies with nucleic acid aptamers while lowering costs has prompted development of new aptamer-protein, siRNA, drug, and nanoparticle conjugates. Specific focal points of this review discuss DNA aptamers covalently bound at their 3' ends to various proteins for enhanced stability and greater pharmacokinetic lifetimes in vivo. The proteins can include Fc tails of IgG for opsonization, and the first component of complement (C1q) to trigger complement-mediated lysis of antibiotic-resistant Gram negative bacteria, cancer cells and possibly some parasites during vulnerable stages. In addition, the 3' protein adduct may be a biotoxin, enzyme, or may simply be human serum albumin (HSA) or a drug known to bind HSA, thereby retarding kidney and other organ clearance and inhibiting serum exonucleases. In this review, the author summarizes existing therapeutic aptamer conjugate categories and describes his patented concept for PCR-based amplification of double-stranded aptamers followed by covalent attachment of proteins or other agents to the chemically vulnerable overhanging 3' adenine added by Taq polymerase. PCR amplification of aptamers could dramatically lower the current $2,000/gram cost of parallel chemical oligonucleotide synthesis, thereby enabling mass production of aptamer-3'-protein or drug conjugates to better compete against expensive humanized monoclonal antibodies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.